DA Davidson Revises Phreesia Price Target Down to $30 While Upholding Buy Outlook
DA Davidson has lowered its price target for healthcare technology company Phreesia Inc. to $30 from $35, continuing to endorse a Buy rating. This assessment follows a discussion with Phreesia’s CFO regarding growth prospects, although recent stock price declines highlight investor concerns. The revised target price implies substantial upside relat…